Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Diagnostic tests Stories

2012-05-22 21:28:08

Lies Van Nieuwenhove, researcher at the Antwerp Institute of Tropical Medicine, has produced proteins imitating typical parts of the sleeping sickness parasite. They can be used in more efficient diagnostic tests, without the need for culturing dangerous parasites. Each year many thousands of Africans contract sleeping sickness. The cause is a unicellular parasite, a trypanosome, which is transmitted by the bite of tsetse flies. First the parasite multiplies in blood and lymph, while...

2012-05-21 10:23:51

SALT LAKE CITY, May 21, 2012 /PRNewswire/ -- Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world. This collaboration highlights the shared purpose of Myriad and Intermountain in...

2012-05-14 02:27:36

SINGAPORE, May 14, 2012 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce the closure of a private placement of 582,510 shares at $1.75 per share (a total of US$$1,019,375.00 raised). The proceeds will in part be used to fund clinical trials of VolitionRX's first NuQ(TM)( )test kits. Shares in the offering were priced at $1.75 per ordinary share, which entitles the holder to one share of common...

2012-05-01 06:27:50

QUEBEC CITY, May 1, 2012 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high value cancer diagnostic tests, issued a statement today commenting on the proposed acquisition of its commercial partner Gen-Probe (Nasdaq: GPRO) by Hologic Inc. (Nasdaq: HOLX). The acquisition, announced yesterday, is being viewed favorably by DiagnoCure management who see an opportunity for the combined companies to put additional resources...

2012-03-30 02:23:17

FDA Approval of The First Molecular Prostate Cancer Test and Decreased Net Loss QUEBEC CITY, March 30, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, today reported financial and operation results for the first quarter 2012 ended January 31, 2012. The Company announced a net loss from continuing operations of $816,164 or $0.02 per share for the first quarter ending January 31,...

2012-03-28 02:24:16

NEW YORK, March 28, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today announced that Kapil Dhingra, M.B, B.S., has joined the Exosome Diagnostics Board of Directors. "I am delighted to join the Board of Exosome Diagnostics at this critical stage in the evolution of the company. Cancer treatment is becoming increasingly personalized. The ability to perform repeated,...

2012-02-01 07:00:00

MUNICH, Feb. 1, 2012 /PRNewswire/ -- Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to...

2012-01-31 10:00:00

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, has introduced a new product line of high medical value biomarkers for response, resistance and pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, a new paradigm in cancer management, partners accurate diagnosis of primary tumor site and predictive biomarkers to drive...

2012-01-26 10:22:18

A new diagnosis technique developed by researchers at the RIKEN Omics Science Center (OSC) has succeeded in detecting influenza virus infection in only 40 minutes and with one hundred times the sensitivity of conventional methods. Clinical research conducted in 2009 and 2010 confirms the new technique accurately identified the 2009 pandemic (pdm) influenza virus in Japanese patients less than 24 hours after fever onset, much faster than standard diagnostic tests. The human-to-human...

2012-01-26 06:00:00

QUEBEC CITY, Jan. 26, 2012 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes high value cancer diagnostic tests, today announced that its partner for the Previstage(TM) GCC Colorectal Cancer Staging Test, Signal Genetics, reported the results of a new study presented on January 21 at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA. The poster entitled "Guanylyl Cyclase C...